Journal article

Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a

Benjamin J Shields, Jacob T Jackson, Donald Metcalf, Wei Shi, Qiutong Huang, Alexandra L Garnham, Stefan P Glaser, Dominik Beck, John E Pimanda, Clifford W Bogue, Gordon K Smyth, Warren S Alexander, Matthew P McCormack

Genes & Development | COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT | Published : 2016


Funding Acknowledgements

We thank Ian Majewski for reagents and helpful comments on the manuscript; Jason Corbin and Jasmin McManus for blood analysis; Waruni Abeysekera for aligning ChIP sequencing reads; Sandra Mifsud, Ladina DiRago, Chayanica Nasa, William Stanley, and Stephen Wilcox for technical assistance; Walter and Eliza Hall Institute Bioservices for mouse husbandry; and the Walter and Eliza Hall Institute Flow Cytometry Facility. We also thank Tobias Herold (Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians-Universitat, Munich, Germany) and Peter J.M. Valk (Department of Hematology and Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands) for providing clinical data. This work was supported by a Program grant (101664 to W.S.A.), Project grants (628386 and 1003391 to M.P.M.), a fellowship (1058344 to W.S.A.), the Independent Research Institutes Infrastructure Support (IRIIS) Scheme from the Australian Government's National Health and Medical Research Council (NHMRC), grants-in-aid from the Cancer Council of Victoria and the Leukemia Foundation of Australia (M.P.M. and S.P.G.), a Future Fellowship from the Australian Research Council (M.P.M.), the Australia Cancer Research Fund (W.S.A.), and a Victorian State Government Operational Infrastructure Support (OIS) Grant.